Table 1.
Health Endpoints
| Health Endpoint | ß -value | Source |
|---|---|---|
| ED visits, O3 | 1.003 per ppb | Zarate-Gonzalez et al (2024)28 |
| ED visits, PM2.5 | 1.012 per µg/m3 | Zarate-Gonzalez et al (2024)28 |
| ED visits, NO2 | 1.023 per ppb | Zarate-Gonzalez et al (2024)28 |
| Hospital visits, PM2.5 | 1.015 per µg/m3 | Zarate-Gonzalez et al (2024)28 |
| Hospital visits, NO2 | 1.028 per ppb | Zarate-Gonzalez et al (2024)28 |
| Hospitalization length of service | Mean 6.3 days per event | Zarate-Gonzalez et al (2024)28 |
| Use of controllers | Mean 4.84 per event | Kattan et al (2005)47 |
| Use of rescue inhalers | Mean 5.95 per event | Kattan et al (2005)47 |
| Cromolyn | Mean 2.64 per event | Kattan et al (2005)47 |
| Use of antibiotics | 0.31–0.58 per event | Kattan et al (2005)47 |
| School absences | Mean 9.2 | Moonie, Sterling, Figgs, and Castro (2006)48 |
| Work loss days >18 - 64 | 0.122 | CHIS (2021)49 |
| Opportunity cost > 65 | Mean 3.5 | Van Der Zee et al (2000)50 |
| Asthma prevalence in the SJV region 2–17 | 0.11 | CHIS (2021)49 |
| Asthma prevalence in the SJV region 18–64 | 0.196 | CHIS (2021)49 |
| Asthma prevalence in the SJV region > 65 | 0.175 | CHIS (2021)52 |